20Aug/13

The US Clinical Research Market Outlook to 2017 – Led by Aging Population … – DigitalJournal.com

The US Clinical Research Market Outlook to 2017 – Led by Aging Population
DigitalJournal.com
The new drugs such as laquinimod, teriflunomide and dimethyl fumarate, and three mAbs— alemtuzumab, daclizumab and rituximab are anticipated to mask the effects and remit the occurrence of multiple sclerosis” – according to the research report ‘The US 

20Aug/13

Cell Therapeutics' Pixuvri gets French marketing nod to treat aggressive B … – pharmabiz.com

Cell Therapeutics’ Pixuvri gets French marketing nod to treat aggressive B
pharmabiz.com
The European Medicines Agency’s (the EMA) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have 

and more »